High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation.
Nonmyeloablative allogeneic transplantation is an emerging therapy for hematologic and solid malignancies and potentially offers patients reduced transplant-related toxicity. Data regarding infectious complications of these protocols are limited, but early studies have demonstrated little infectious morbidity, particularly low rates of invasive fungal infections (IFIs). In the present study, 31 consecutive cases of nonmyeloablative transplantation were reviewed over a 2.5-year period, with a specific focus on infectious complications. Twenty-six patients (84%) had at least 1 significant infection during the year after transplantation, and infection-related mortality was 37%. Cytomegalovirus end-organ disease was diagnosed in 3 patients (10%). Ten patients (32%) were given the diagnosis of IFI; 7 (23%) met criteria for proven IFI. Fungal-related mortality was 80% within the group of patients with IFI and accounted for a significant portion of the overall mortality in the study. Severe graft-versus-host disease, high-dose corticosteroid use, recurrent neutropenia, and relapsed or refractory disease were factors associated with development of IFI.
Hagen
Elisabeth A
EA
Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4283, USA.
Stern
Hillary
H
Porter
David
D
Duffy
Kathleen
K
Foley
Karen
K
Luger
Selina
S
Schuster
Stephen J
SJ
Stadtmauer
Edward A
EA
Schuster
Mindy G
MG
D000328:Adult; D000368:Aged; D018890:Chemoprevention; D005260:Female; D005334:Fever / Q000209:etiology; D006086:Graft vs Host Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D009503:Neutropenia / Q000209:etiology; D011183:Postoperative Complications / Q000453:epidemiology* / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D014184:Transplantation, Homologous / Q000009:adverse effects*; D016896:Treatment Outcome